tetano
Editor, Senior Moderator
Travel Med Infect Dis. 2020 May 6:101735. doi: 10.1016/j.tmaid.2020.101735. [Epub ahead of print]
Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
Hashem AM[SUP]1[/SUP], Alghamdi BS[SUP]2[/SUP], Algaissi AA[SUP]3[/SUP], Alshehri FS[SUP]4[/SUP], Bukhari A[SUP]5[/SUP], Alfaleh MA[SUP]6[/SUP], Memish ZA[SUP]7[/SUP].
Author information
Abstract
The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rational the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.
Copyright ? 2020. Published by Elsevier Ltd.
KEYWORDS:
COVID-19; Chloroquine; Hydroxychloroquine; SARS-CoV-2
PMID:32387694DOI:10.1016/j.tmaid.2020.101735
Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
Hashem AM[SUP]1[/SUP], Alghamdi BS[SUP]2[/SUP], Algaissi AA[SUP]3[/SUP], Alshehri FS[SUP]4[/SUP], Bukhari A[SUP]5[/SUP], Alfaleh MA[SUP]6[/SUP], Memish ZA[SUP]7[/SUP].
Author information
Abstract
The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rational the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.
Copyright ? 2020. Published by Elsevier Ltd.
KEYWORDS:
COVID-19; Chloroquine; Hydroxychloroquine; SARS-CoV-2
PMID:32387694DOI:10.1016/j.tmaid.2020.101735